The contribution of mosaicism to genetic diseases and de novo pathogenic variants.
Rory J TinkerLisa BastaracheKimberly EzellShilpa Nadimpalli KobrenCecilia EstevesJill A RosenfeldEllen F MacnamaraRizwan HamidJoy D CoganDavid RinkerSouhrid MukharjeeIan GlassKatrina DippleJohn A Phillipsnull nullPublished in: American journal of medical genetics. Part A (2023)
The contribution of mosaicism to diagnosed genetic disease and presumed de novo variants (DNV) is under investigated. We determined the contribution of mosaic genetic disease (MGD) and diagnosed parental mosaicism (PM) in parents of offspring with reported DNV (in the same variant) in the (1) Undiagnosed Diseases Network (UDN) (N = 1946) and (2) in 12,472 individuals electronic health records (EHR) who underwent genetic testing at an academic medical center. In the UDN, we found 4.51% of diagnosed probands had MGD, and 2.86% of parents of those with DNV exhibited PM. In the EHR, we found 6.03% and 2.99% and (of diagnosed probands) had MGD detected on chromosomal microarray and exome/genome sequencing, respectively. We found 2.34% (of those with a presumed pathogenic DNV) had a parent with PM for the variant. We detected mosaicism (regardless of pathogenicity) in 4.49% of genetic tests performed. We found a broad phenotypic spectrum of MGD with previously unknown phenotypic phenomena. MGD is highly heterogeneous and provides a significant contribution to genetic diseases. Further work is required to improve the diagnosis of MGD and investigate how PM contributes to DNV risk.
Keyphrases
- copy number
- electronic health record
- genome wide
- particulate matter
- air pollution
- heavy metals
- polycyclic aromatic hydrocarbons
- gene expression
- dna methylation
- metabolic syndrome
- adipose tissue
- staphylococcus aureus
- single cell
- risk assessment
- skeletal muscle
- high speed
- insulin resistance
- pseudomonas aeruginosa
- candida albicans